Result

Search results for the GEO ID: GSE26704

(Click on the check boxes provided under "Select for analysis", to initiate grouping)

(Once the selection is made, click on "Add groups" in "Make groups for comparison", to make a group. Scroll down)

GSM ID

GPL ID

Select for analysis

Title

Source name

Description

Characteristics

GSM657239

GPL570

H460v-control

cell line: non small cell lung cancer cell line H460 genotype/variation: wild type agent: untreated (control)

07SE213

Sample_geo_accession	GSM657239
Sample_status	Public on Jan 01 2012
Sample_submission_date	Jan 19 2011
Sample_last_update_date	Jan 01 2012
Sample_type	RNA
Sample_channel_count	1
Sample_organism_ch1	Homo sapiens
Sample_taxid_ch1	9606
Sample_treatment_protocol_ch1	The DUSP1 pSuperRetro-derived vectors were constructed as described (Chattoppadhyay et al., 2006). Clones expressing siRNA for DUSP1 were selected for their ability to grow in the presence of puromycin and kept for selection. Stable transfection was confirmed by qRT-PCR and Western Blot.Cisplatin (CCDP) was purchased by Farma Ferrer (Barcelona, Spain). Cells were treated with 10 µg/mL CDDP for 1, 3 and 6 hours.
Sample_growth_protocol_ch1	The human non small lung cancer cell line H460 used in this study was from ATCC (American Type Culture Collection). The cell line was maintained in Roswell Park Memorial Institute (RPMI) (Gibco, Invitrogen) supplemented with 10% bovine serum and transfected by Lipofectamine Plus Reagent from Life Technologies as directed by the manufacturer.
Sample_molecule_ch1	total RNA
Sample_extract_protocol_ch1	The cells were harvested with TRIzol Reagent (Invitrogen) and the RNA was extracted according to the manufacturer's instructions. As a last step of the extraction procedure, the RNA was purified with the RNeasy Mini-kit (Qiagen, Hilden, Germany). The RNA quality was confirmed by the ratio of 28S and 18S rRNA after agarose gel electrophoresis.
Sample_label_ch1	biotin
Sample_label_protocol_ch1	The cDNA was prepared from 2 microg total RNA using the One –Cycle cDNA Synthesis kit from Affymetrix. This cDNA was used for synthezising the cRNA using the IVT labeling kit (Affimetrix). The synthezised cRNA was purified with the GeneChip Sample Cleanup Module (Affimetrix).
Sample_hyb_protocol	Following fragmentation, 15 microg of cRNA were hybridized to the Affymetrix HG-U133A 2.0 chip according to the protocols provided by the manufacturer.
Sample_scan_protocol	GeneChips were scanned using the GeneChip Scanner 3000 from Affymetrix.
Sample_data_processing	RMA
Sample_platform_id	GPL570
Sample_contact_name	Eva,,Bandres
Sample_contact_email	ebandres@unav.es
Sample_contact_laboratory	Pharmacogenomics lab
Sample_contact_department	Cancer Research Program
Sample_contact_institute	Center for Applied Medical Research (CIMA), University of Navarra
Sample_contact_address	Avda Pio XII, 55
Sample_contact_city	Pamplona
Sample_contact_zip/postal_code	31008
Sample_contact_country	Spain
Sample_supplementary_file	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM657nnn/GSM657239/suppl/GSM657239.CEL.gz
Sample_series_id	GSE26704
Sample_data_row_count	54675

GSM657240

GPL570

H460cri-control

cell line: non small cell lung cancer cell line H460 genotype/variation: DUSP1 knockdown (siRNA-mediated) agent: untreated (control)

07SE214

Sample_geo_accession	GSM657240
Sample_status	Public on Jan 01 2012
Sample_submission_date	Jan 19 2011
Sample_last_update_date	Jan 01 2012
Sample_type	RNA
Sample_channel_count	1
Sample_organism_ch1	Homo sapiens
Sample_taxid_ch1	9606
Sample_treatment_protocol_ch1	The DUSP1 pSuperRetro-derived vectors were constructed as described (Chattoppadhyay et al., 2006). Clones expressing siRNA for DUSP1 were selected for their ability to grow in the presence of puromycin and kept for selection. Stable transfection was confirmed by qRT-PCR and Western Blot.Cisplatin (CCDP) was purchased by Farma Ferrer (Barcelona, Spain). Cells were treated with 10 µg/mL CDDP for 1, 3 and 6 hours.
Sample_growth_protocol_ch1	The human non small lung cancer cell line H460 used in this study was from ATCC (American Type Culture Collection). The cell line was maintained in Roswell Park Memorial Institute (RPMI) (Gibco, Invitrogen) supplemented with 10% bovine serum and transfected by Lipofectamine Plus Reagent from Life Technologies as directed by the manufacturer.
Sample_molecule_ch1	total RNA
Sample_extract_protocol_ch1	The cells were harvested with TRIzol Reagent (Invitrogen) and the RNA was extracted according to the manufacturer's instructions. As a last step of the extraction procedure, the RNA was purified with the RNeasy Mini-kit (Qiagen, Hilden, Germany). The RNA quality was confirmed by the ratio of 28S and 18S rRNA after agarose gel electrophoresis.
Sample_label_ch1	biotin
Sample_label_protocol_ch1	The cDNA was prepared from 2 microg total RNA using the One –Cycle cDNA Synthesis kit from Affymetrix. This cDNA was used for synthezising the cRNA using the IVT labeling kit (Affimetrix). The synthezised cRNA was purified with the GeneChip Sample Cleanup Module (Affimetrix).
Sample_hyb_protocol	Following fragmentation, 15 microg of cRNA were hybridized to the Affymetrix HG-U133A 2.0 chip according to the protocols provided by the manufacturer.
Sample_scan_protocol	GeneChips were scanned using the GeneChip Scanner 3000 from Affymetrix.
Sample_data_processing	RMA
Sample_platform_id	GPL570
Sample_contact_name	Eva,,Bandres
Sample_contact_email	ebandres@unav.es
Sample_contact_laboratory	Pharmacogenomics lab
Sample_contact_department	Cancer Research Program
Sample_contact_institute	Center for Applied Medical Research (CIMA), University of Navarra
Sample_contact_address	Avda Pio XII, 55
Sample_contact_city	Pamplona
Sample_contact_zip/postal_code	31008
Sample_contact_country	Spain
Sample_supplementary_file	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM657nnn/GSM657240/suppl/GSM657240.CEL.gz
Sample_series_id	GSE26704
Sample_data_row_count	54675

GSM657241

GPL570

H460v-CCDP 1hour

cell line: non small cell lung cancer cell line H460 genotype/variation: wild type agent: CCDP time: 1 hour

07SE215

Sample_geo_accession	GSM657241
Sample_status	Public on Jan 01 2012
Sample_submission_date	Jan 19 2011
Sample_last_update_date	Jan 01 2012
Sample_type	RNA
Sample_channel_count	1
Sample_organism_ch1	Homo sapiens
Sample_taxid_ch1	9606
Sample_treatment_protocol_ch1	The DUSP1 pSuperRetro-derived vectors were constructed as described (Chattoppadhyay et al., 2006). Clones expressing siRNA for DUSP1 were selected for their ability to grow in the presence of puromycin and kept for selection. Stable transfection was confirmed by qRT-PCR and Western Blot.Cisplatin (CCDP) was purchased by Farma Ferrer (Barcelona, Spain). Cells were treated with 10 µg/mL CDDP for 1, 3 and 6 hours.
Sample_growth_protocol_ch1	The human non small lung cancer cell line H460 used in this study was from ATCC (American Type Culture Collection). The cell line was maintained in Roswell Park Memorial Institute (RPMI) (Gibco, Invitrogen) supplemented with 10% bovine serum and transfected by Lipofectamine Plus Reagent from Life Technologies as directed by the manufacturer.
Sample_molecule_ch1	total RNA
Sample_extract_protocol_ch1	The cells were harvested with TRIzol Reagent (Invitrogen) and the RNA was extracted according to the manufacturer's instructions. As a last step of the extraction procedure, the RNA was purified with the RNeasy Mini-kit (Qiagen, Hilden, Germany). The RNA quality was confirmed by the ratio of 28S and 18S rRNA after agarose gel electrophoresis.
Sample_label_ch1	biotin
Sample_label_protocol_ch1	The cDNA was prepared from 2 microg total RNA using the One –Cycle cDNA Synthesis kit from Affymetrix. This cDNA was used for synthezising the cRNA using the IVT labeling kit (Affimetrix). The synthezised cRNA was purified with the GeneChip Sample Cleanup Module (Affimetrix).
Sample_hyb_protocol	Following fragmentation, 15 microg of cRNA were hybridized to the Affymetrix HG-U133A 2.0 chip according to the protocols provided by the manufacturer.
Sample_scan_protocol	GeneChips were scanned using the GeneChip Scanner 3000 from Affymetrix.
Sample_data_processing	RMA
Sample_platform_id	GPL570
Sample_contact_name	Eva,,Bandres
Sample_contact_email	ebandres@unav.es
Sample_contact_laboratory	Pharmacogenomics lab
Sample_contact_department	Cancer Research Program
Sample_contact_institute	Center for Applied Medical Research (CIMA), University of Navarra
Sample_contact_address	Avda Pio XII, 55
Sample_contact_city	Pamplona
Sample_contact_zip/postal_code	31008
Sample_contact_country	Spain
Sample_supplementary_file	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM657nnn/GSM657241/suppl/GSM657241.CEL.gz
Sample_series_id	GSE26704
Sample_data_row_count	54675

GSM657242

GPL570

H460cri-CCDP 1hour

cell line: non small cell lung cancer cell line H460 genotype/variation: DUSP1 knockdown (siRNA-mediated) agent: CCDP time: 1 hour

07SE216

Sample_geo_accession	GSM657242
Sample_status	Public on Jan 01 2012
Sample_submission_date	Jan 19 2011
Sample_last_update_date	Jan 01 2012
Sample_type	RNA
Sample_channel_count	1
Sample_organism_ch1	Homo sapiens
Sample_taxid_ch1	9606
Sample_treatment_protocol_ch1	The DUSP1 pSuperRetro-derived vectors were constructed as described (Chattoppadhyay et al., 2006). Clones expressing siRNA for DUSP1 were selected for their ability to grow in the presence of puromycin and kept for selection. Stable transfection was confirmed by qRT-PCR and Western Blot.Cisplatin (CCDP) was purchased by Farma Ferrer (Barcelona, Spain). Cells were treated with 10 µg/mL CDDP for 1, 3 and 6 hours.
Sample_growth_protocol_ch1	The human non small lung cancer cell line H460 used in this study was from ATCC (American Type Culture Collection). The cell line was maintained in Roswell Park Memorial Institute (RPMI) (Gibco, Invitrogen) supplemented with 10% bovine serum and transfected by Lipofectamine Plus Reagent from Life Technologies as directed by the manufacturer.
Sample_molecule_ch1	total RNA
Sample_extract_protocol_ch1	The cells were harvested with TRIzol Reagent (Invitrogen) and the RNA was extracted according to the manufacturer's instructions. As a last step of the extraction procedure, the RNA was purified with the RNeasy Mini-kit (Qiagen, Hilden, Germany). The RNA quality was confirmed by the ratio of 28S and 18S rRNA after agarose gel electrophoresis.
Sample_label_ch1	biotin
Sample_label_protocol_ch1	The cDNA was prepared from 2 microg total RNA using the One –Cycle cDNA Synthesis kit from Affymetrix. This cDNA was used for synthezising the cRNA using the IVT labeling kit (Affimetrix). The synthezised cRNA was purified with the GeneChip Sample Cleanup Module (Affimetrix).
Sample_hyb_protocol	Following fragmentation, 15 microg of cRNA were hybridized to the Affymetrix HG-U133A 2.0 chip according to the protocols provided by the manufacturer.
Sample_scan_protocol	GeneChips were scanned using the GeneChip Scanner 3000 from Affymetrix.
Sample_data_processing	RMA
Sample_platform_id	GPL570
Sample_contact_name	Eva,,Bandres
Sample_contact_email	ebandres@unav.es
Sample_contact_laboratory	Pharmacogenomics lab
Sample_contact_department	Cancer Research Program
Sample_contact_institute	Center for Applied Medical Research (CIMA), University of Navarra
Sample_contact_address	Avda Pio XII, 55
Sample_contact_city	Pamplona
Sample_contact_zip/postal_code	31008
Sample_contact_country	Spain
Sample_supplementary_file	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM657nnn/GSM657242/suppl/GSM657242.CEL.gz
Sample_series_id	GSE26704
Sample_data_row_count	54675

GSM657243

GPL570

H460v-CCDP 3 hour

cell line: non small cell lung cancer cell line H460 genotype/variation: wild type agent: CCDP time: 3 hour

07SE217

Sample_geo_accession	GSM657243
Sample_status	Public on Jan 01 2012
Sample_submission_date	Jan 19 2011
Sample_last_update_date	Jan 01 2012
Sample_type	RNA
Sample_channel_count	1
Sample_organism_ch1	Homo sapiens
Sample_taxid_ch1	9606
Sample_treatment_protocol_ch1	The DUSP1 pSuperRetro-derived vectors were constructed as described (Chattoppadhyay et al., 2006). Clones expressing siRNA for DUSP1 were selected for their ability to grow in the presence of puromycin and kept for selection. Stable transfection was confirmed by qRT-PCR and Western Blot.Cisplatin (CCDP) was purchased by Farma Ferrer (Barcelona, Spain). Cells were treated with 10 µg/mL CDDP for 1, 3 and 6 hours.
Sample_growth_protocol_ch1	The human non small lung cancer cell line H460 used in this study was from ATCC (American Type Culture Collection). The cell line was maintained in Roswell Park Memorial Institute (RPMI) (Gibco, Invitrogen) supplemented with 10% bovine serum and transfected by Lipofectamine Plus Reagent from Life Technologies as directed by the manufacturer.
Sample_molecule_ch1	total RNA
Sample_extract_protocol_ch1	The cells were harvested with TRIzol Reagent (Invitrogen) and the RNA was extracted according to the manufacturer's instructions. As a last step of the extraction procedure, the RNA was purified with the RNeasy Mini-kit (Qiagen, Hilden, Germany). The RNA quality was confirmed by the ratio of 28S and 18S rRNA after agarose gel electrophoresis.
Sample_label_ch1	biotin
Sample_label_protocol_ch1	The cDNA was prepared from 2 microg total RNA using the One –Cycle cDNA Synthesis kit from Affymetrix. This cDNA was used for synthezising the cRNA using the IVT labeling kit (Affimetrix). The synthezised cRNA was purified with the GeneChip Sample Cleanup Module (Affimetrix).
Sample_hyb_protocol	Following fragmentation, 15 microg of cRNA were hybridized to the Affymetrix HG-U133A 2.0 chip according to the protocols provided by the manufacturer.
Sample_scan_protocol	GeneChips were scanned using the GeneChip Scanner 3000 from Affymetrix.
Sample_data_processing	RMA
Sample_platform_id	GPL570
Sample_contact_name	Eva,,Bandres
Sample_contact_email	ebandres@unav.es
Sample_contact_laboratory	Pharmacogenomics lab
Sample_contact_department	Cancer Research Program
Sample_contact_institute	Center for Applied Medical Research (CIMA), University of Navarra
Sample_contact_address	Avda Pio XII, 55
Sample_contact_city	Pamplona
Sample_contact_zip/postal_code	31008
Sample_contact_country	Spain
Sample_supplementary_file	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM657nnn/GSM657243/suppl/GSM657243.CEL.gz
Sample_series_id	GSE26704
Sample_data_row_count	54675

GSM657244

GPL570

H460cri-CCDP 3 hour

cell line: non small cell lung cancer cell line H460 genotype/variation: DUSP1 knockdown (siRNA-mediated) agent: CCDP time: 3 hour

07SE218

Sample_geo_accession	GSM657244
Sample_status	Public on Jan 01 2012
Sample_submission_date	Jan 19 2011
Sample_last_update_date	Jan 01 2012
Sample_type	RNA
Sample_channel_count	1
Sample_organism_ch1	Homo sapiens
Sample_taxid_ch1	9606
Sample_treatment_protocol_ch1	The DUSP1 pSuperRetro-derived vectors were constructed as described (Chattoppadhyay et al., 2006). Clones expressing siRNA for DUSP1 were selected for their ability to grow in the presence of puromycin and kept for selection. Stable transfection was confirmed by qRT-PCR and Western Blot.Cisplatin (CCDP) was purchased by Farma Ferrer (Barcelona, Spain). Cells were treated with 10 µg/mL CDDP for 1, 3 and 6 hours.
Sample_growth_protocol_ch1	The human non small lung cancer cell line H460 used in this study was from ATCC (American Type Culture Collection). The cell line was maintained in Roswell Park Memorial Institute (RPMI) (Gibco, Invitrogen) supplemented with 10% bovine serum and transfected by Lipofectamine Plus Reagent from Life Technologies as directed by the manufacturer.
Sample_molecule_ch1	total RNA
Sample_extract_protocol_ch1	The cells were harvested with TRIzol Reagent (Invitrogen) and the RNA was extracted according to the manufacturer's instructions. As a last step of the extraction procedure, the RNA was purified with the RNeasy Mini-kit (Qiagen, Hilden, Germany). The RNA quality was confirmed by the ratio of 28S and 18S rRNA after agarose gel electrophoresis.
Sample_label_ch1	biotin
Sample_label_protocol_ch1	The cDNA was prepared from 2 microg total RNA using the One –Cycle cDNA Synthesis kit from Affymetrix. This cDNA was used for synthezising the cRNA using the IVT labeling kit (Affimetrix). The synthezised cRNA was purified with the GeneChip Sample Cleanup Module (Affimetrix).
Sample_hyb_protocol	Following fragmentation, 15 microg of cRNA were hybridized to the Affymetrix HG-U133A 2.0 chip according to the protocols provided by the manufacturer.
Sample_scan_protocol	GeneChips were scanned using the GeneChip Scanner 3000 from Affymetrix.
Sample_data_processing	RMA
Sample_platform_id	GPL570
Sample_contact_name	Eva,,Bandres
Sample_contact_email	ebandres@unav.es
Sample_contact_laboratory	Pharmacogenomics lab
Sample_contact_department	Cancer Research Program
Sample_contact_institute	Center for Applied Medical Research (CIMA), University of Navarra
Sample_contact_address	Avda Pio XII, 55
Sample_contact_city	Pamplona
Sample_contact_zip/postal_code	31008
Sample_contact_country	Spain
Sample_supplementary_file	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM657nnn/GSM657244/suppl/GSM657244.CEL.gz
Sample_series_id	GSE26704
Sample_data_row_count	54675

GSM657245

GPL570

H460v-CCDP 6hour

cell line: non small cell lung cancer cell line H460 genotype/variation: wild type agent: CCDP time: 6 hour

07SE219

Sample_geo_accession	GSM657245
Sample_status	Public on Jan 01 2012
Sample_submission_date	Jan 19 2011
Sample_last_update_date	Jan 01 2012
Sample_type	RNA
Sample_channel_count	1
Sample_organism_ch1	Homo sapiens
Sample_taxid_ch1	9606
Sample_treatment_protocol_ch1	The DUSP1 pSuperRetro-derived vectors were constructed as described (Chattoppadhyay et al., 2006). Clones expressing siRNA for DUSP1 were selected for their ability to grow in the presence of puromycin and kept for selection. Stable transfection was confirmed by qRT-PCR and Western Blot.Cisplatin (CCDP) was purchased by Farma Ferrer (Barcelona, Spain). Cells were treated with 10 µg/mL CDDP for 1, 3 and 6 hours.
Sample_growth_protocol_ch1	The human non small lung cancer cell line H460 used in this study was from ATCC (American Type Culture Collection). The cell line was maintained in Roswell Park Memorial Institute (RPMI) (Gibco, Invitrogen) supplemented with 10% bovine serum and transfected by Lipofectamine Plus Reagent from Life Technologies as directed by the manufacturer.
Sample_molecule_ch1	total RNA
Sample_extract_protocol_ch1	The cells were harvested with TRIzol Reagent (Invitrogen) and the RNA was extracted according to the manufacturer's instructions. As a last step of the extraction procedure, the RNA was purified with the RNeasy Mini-kit (Qiagen, Hilden, Germany). The RNA quality was confirmed by the ratio of 28S and 18S rRNA after agarose gel electrophoresis.
Sample_label_ch1	biotin
Sample_label_protocol_ch1	The cDNA was prepared from 2 microg total RNA using the One –Cycle cDNA Synthesis kit from Affymetrix. This cDNA was used for synthezising the cRNA using the IVT labeling kit (Affimetrix). The synthezised cRNA was purified with the GeneChip Sample Cleanup Module (Affimetrix).
Sample_hyb_protocol	Following fragmentation, 15 microg of cRNA were hybridized to the Affymetrix HG-U133A 2.0 chip according to the protocols provided by the manufacturer.
Sample_scan_protocol	GeneChips were scanned using the GeneChip Scanner 3000 from Affymetrix.
Sample_data_processing	RMA
Sample_platform_id	GPL570
Sample_contact_name	Eva,,Bandres
Sample_contact_email	ebandres@unav.es
Sample_contact_laboratory	Pharmacogenomics lab
Sample_contact_department	Cancer Research Program
Sample_contact_institute	Center for Applied Medical Research (CIMA), University of Navarra
Sample_contact_address	Avda Pio XII, 55
Sample_contact_city	Pamplona
Sample_contact_zip/postal_code	31008
Sample_contact_country	Spain
Sample_supplementary_file	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM657nnn/GSM657245/suppl/GSM657245.CEL.gz
Sample_series_id	GSE26704
Sample_data_row_count	54675

GSM657246

GPL570

H460cri-CCDP 6hour

cell line: non small cell lung cancer cell line H460 genotype/variation: DUSP1 knockdown (siRNA-mediated) agent: CCDP time: 6 hour

07SE220

Sample_geo_accession	GSM657246
Sample_status	Public on Jan 01 2012
Sample_submission_date	Jan 19 2011
Sample_last_update_date	Jan 01 2012
Sample_type	RNA
Sample_channel_count	1
Sample_organism_ch1	Homo sapiens
Sample_taxid_ch1	9606
Sample_treatment_protocol_ch1	The DUSP1 pSuperRetro-derived vectors were constructed as described (Chattoppadhyay et al., 2006). Clones expressing siRNA for DUSP1 were selected for their ability to grow in the presence of puromycin and kept for selection. Stable transfection was confirmed by qRT-PCR and Western Blot.Cisplatin (CCDP) was purchased by Farma Ferrer (Barcelona, Spain). Cells were treated with 10 µg/mL CDDP for 1, 3 and 6 hours.
Sample_growth_protocol_ch1	The human non small lung cancer cell line H460 used in this study was from ATCC (American Type Culture Collection). The cell line was maintained in Roswell Park Memorial Institute (RPMI) (Gibco, Invitrogen) supplemented with 10% bovine serum and transfected by Lipofectamine Plus Reagent from Life Technologies as directed by the manufacturer.
Sample_molecule_ch1	total RNA
Sample_extract_protocol_ch1	The cells were harvested with TRIzol Reagent (Invitrogen) and the RNA was extracted according to the manufacturer's instructions. As a last step of the extraction procedure, the RNA was purified with the RNeasy Mini-kit (Qiagen, Hilden, Germany). The RNA quality was confirmed by the ratio of 28S and 18S rRNA after agarose gel electrophoresis.
Sample_label_ch1	biotin
Sample_label_protocol_ch1	The cDNA was prepared from 2 microg total RNA using the One –Cycle cDNA Synthesis kit from Affymetrix. This cDNA was used for synthezising the cRNA using the IVT labeling kit (Affimetrix). The synthezised cRNA was purified with the GeneChip Sample Cleanup Module (Affimetrix).
Sample_hyb_protocol	Following fragmentation, 15 microg of cRNA were hybridized to the Affymetrix HG-U133A 2.0 chip according to the protocols provided by the manufacturer.
Sample_scan_protocol	GeneChips were scanned using the GeneChip Scanner 3000 from Affymetrix.
Sample_data_processing	RMA
Sample_platform_id	GPL570
Sample_contact_name	Eva,,Bandres
Sample_contact_email	ebandres@unav.es
Sample_contact_laboratory	Pharmacogenomics lab
Sample_contact_department	Cancer Research Program
Sample_contact_institute	Center for Applied Medical Research (CIMA), University of Navarra
Sample_contact_address	Avda Pio XII, 55
Sample_contact_city	Pamplona
Sample_contact_zip/postal_code	31008
Sample_contact_country	Spain
Sample_supplementary_file	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM657nnn/GSM657246/suppl/GSM657246.CEL.gz
Sample_series_id	GSE26704
Sample_data_row_count	54675

Make groups for comparisons

(2 groups will be compared at a time)

Select GSMs and click on "Add groups"

Enter the group name here:

Select expression type

Transcripts profile based on;

A. Differential status (Up/Down regulation)

B. Absolute calls (Transcribed/Not-detected)

Filter results by number of probes